Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company, which engages in discovery, research, development, and manufacturing of differentiated antibody therapies in therapeutic areas with high unmet medical needs. It focuses on oncology, nephrology, and bone diseases. The firm also develops Immune Tolerance Breaking technology platform to build a diversified and risk-balanced pipeline of antibodies. The company was founded on August 20, 2010 and is headquartered in Suzhou, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company